AFP and hepatocellular carcinoma: Although the controversial effects of E2F8 existed in regulation of cell cycle progression and tumor angiogenesis, our findings supported the conclusion that E2F8 was overexpressed in tumors, correlated with advanced tumor stage and high AFP level, and poor survivals in HCC patients, indicating that E2F8 should be a potential therapeutic target for HCC treatment [36].